Ignite Creation Date:
2024-05-06 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 2:13 PM
Study NCT ID:
NCT05036759
Status:
UNKNOWN
Last Update Posted:
2021-09-08
First Post:
2021-08-30
Brief Title:
68Ga-FAPI PETMR for Atherosclerosis
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
68Ga-FAPI PETMR for Intracranial and Carotid Atherosclerosis
Status:
UNKNOWN
Status Verified Date:
2021-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque Fibroblast activating protein FAP is an active serine protease which can degrade type I collagen potentially thinning the fibrous cap Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PETMR
Detailed Description:
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque Fibroblast activating protein FAP is an active serine protease which can degrade type I collagen potentially thinning the fibrous cap Previous ex vivo analysis of human aortic atheromata revealed that FAP was expressed in atherosclerotic plaques and higher FAP expression was detected in thin fibrous caps than thick caps Constitutive Fap deletion in atherosclerosis-prone mice models could reduce plaque formation and improve plaque stability with increased fibrous cap thickness Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PETMR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None